{"preliminary_commentary":{"by_channel":{"x_thread":6,"podcast":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"name":"SKYSCRAPER-05","nct_id":"NCT04832854","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=skyscraper-05-nct04832854. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Participants with high programmed death-ligand 1 (PD-L1) expression level will be enrolled in Cohort A and receive neoadjuvant atezolizumab plus tiragolumab for 4 cycles, followed by surgical resection and either adjuvant atezolizumab plus tiragolumab for 16 cycles or adjuvant chemotherapy for 4 cycles at the discretion of the investigator.\n\nChemotherapy may include:\n\n* cisplatin/carboplatin + pemetrexed (for non-squamous only)\n* carboplatin + gemcitabine (for squamous only)\n* carboplatin + paclitaxel","label":"Cohort A (PD-L1 High)","type":"EXPERIMENTAL"},{"description":"All comers, which are participants with any PD-L1 expression level, will be enrolled in Cohort B and receive neoadjuvant atezolizumab plus tiragolumab plus chemotherapy for 4 cycles, followed by surgical resection and adjuvant atezolizumab plus tiragolumab for 16 cycles.\n\nChemotherapy may include:\n\n* cisplatin/carboplatin + pemetrexed (for non-squamous only)\n* carboplatin + gemcitabine (for squamous only)\n* carboplatin + paclitaxel","label":"Cohort B (PD-L1 All Comers)","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2025-03-05","type":"ACTUAL"},"conditions":["Non-Small Cell Lung Cancer (NSCLC)"],"enrollment":{"count":50,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Atezolizumab","otherNames":["Tecentriq"],"type":"DRUG"},{"name":"Tiragolumab","otherNames":["MTIG7192A"],"type":"DRUG"},{"name":"Carboplatin","otherNames":[],"type":"DRUG"},{"name":"Cisplatin","otherNames":[],"type":"DRUG"},{"name":"Pemetrexed","otherNames":[],"type":"DRUG"},{"name":"Gemcitabine","otherNames":[],"type":"DRUG"},{"name":"Paclitaxel","otherNames":[],"type":"DRUG"}],"last_update":"2026-03-11","lead_sponsor":"Hoffmann-La Roche","official_title":"A Phase II, Open-Label, Multicenter Study Evaluating the Safety and Efficacy of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab, With or Without Platinum-Based Chemotherapy, in Patients With Previously Untreated Locally Advanced Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer","overall_status":"TERMINATED","phases":["PHASE2"],"primary_completion_date":{"date":"2025-03-05","type":"ACTUAL"},"primary_outcomes":[{"measure":"Number of Participants With Surgical Delays","timeFrame":"Up to approximately 4.7 months"},{"measure":"Number of Participants With Operative and Post-operative Complications","timeFrame":"From day of surgery up to end of safety follow-up (up to approximately 17.5 months)"},{"measure":"Number of Participants With Surgical Cancellations Related to Study Treatment","timeFrame":"Up to approximately 4.7 months"},{"measure":"Number of Participants With Adverse Events (AEs)","timeFrame":"From signing of informed consent to up to 90 days after the final dose of study treatment (Up to approximately 1.7 years)"},{"measure":"Major Pathological Response (MPR) Rate","timeFrame":"At the time of surgical resection (From Day 114 to Day 144)"}],"references":[],"start_date":{"date":"2021-04-23","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study Evaluating the Safety and Efficacy of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab, With or Without Platinum-Based Chemotherapy, in Participants With Previously Untreated Locally Advanced Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer","url":"https://clinicaltrials.gov/study/NCT04832854"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/skyscraper-05-nct04832854"}